Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events:
-
2024 Wells Fargo Healthcare Conference, Boston, MA
- Meetings only on September 4, 2024
-
H.C. Wainwright 26th Annual Global Investor Conference, New York, NY
- Meetings and fireside chat on September 10, 2024 at 3:30pm ET
-
2024 Cantor Global Healthcare Conference, New York, NY
- Meetings only on September 18, 2024
Please check with each conference sponsor to arrange 1x1 meetings.
Webcast information for the fireside chat will be available at https://xerispharma.com/investor-relations.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect®, to support long-term product development and commercial success.
Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow Xeris on Twitter, LinkedIn or Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822640280/en/
